Dendritic cell vaccines to combat glioblastoma

References

• Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res.61, 842–847 (2001).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Irie M et al. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother.50, 337–344 (2001).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer89(7), 1172–1179 (2003).
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific cytotoxic T cells in patients with malignant glioma. Cancer Res.64(14), 4973–4979 (2004).
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Van Calenbergh F, Demaerel P et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. J. Neurosurg.100(5 Suppl.), 492–497 (2004).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res.11(11), 4160–4167 (2005).
   PubMed Web of Science ®Google Scholar
• Liau LM, Prins RM, Kiertscher SM et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res.11(15), 5515–5525 (2005).
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiform to chemotherapy after vaccination. Clin. Cancer Res.10(16), 5316–5326 (2004).
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Black KL, Liu G et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res.68(14), 5955–5964 (2008).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Bigner DD et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J. Clin. Oncol.26(Suppl.), S92 (2008) (Abstract 2011).
   Google Scholar
• Liénard D, Rimoldi D, Marchand M et al.Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immunol. Immunother.4, 4 (2004).
   Google Scholar
• Walker EB, Haley D, Miller W et al. gp100(209–2M) peptide immunization of human lymphocyte antigen-A2+ stage I–III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin. Cancer Res.10(2), 668–680 (2004).
   PubMed Web of Science ®Google Scholar
• Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and Phase I clinical trials of peptide-based vaccination. Cancer Immunol. Immunother.53(3), 249–255 (2004).
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16), 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar
• Freije WA, Castro-Vargas FE, Fang Z et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res.64(18), 6503–6510 (2004).
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell9(3), 157–173 (2006).
   PubMed Web of Science ®Google Scholar
• Pellegatta S, Poliani PL, Corno D et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res.66(21), 10247–10252 (2006).
   PubMed Web of Science ®Google Scholar
• Xu Q, Liu G, Yuan X et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells27(8), 1734–1740 (2009).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Mitchell DA et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol. Cancer Ther.8(10), 2773–2779 (2009).
   PubMed Web of Science ®Google Scholar
• Brooks WH, Roszman TL, Mahaley MS, Woosley RE. Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours. Clin. Exp. Immunol.29, 61–66 (1977).
   PubMed Web of Science ®Google Scholar
• Mahaley MS Jr, Brooks WH, Roszman TL et al. Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J. Neurosurg.46, 467–476 (1977).
   PubMed Web of Science ®Google Scholar
• Prins RM, Incardona F, Lau R et al. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity. J. Immunol.172(3), 1602–1611 (2004).
   PubMedGoogle Scholar